{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:09:07Z","timestamp":1778717347565,"version":"3.51.4"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2020,10,30]],"date-time":"2020-10-30T00:00:00Z","timestamp":1604016000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,30]],"date-time":"2020-10-30T00:00:00Z","timestamp":1604016000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum M\u00fcnster"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Strahlenther Onkol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Purpose<\/jats:title>\n<jats:p>The coronavirus pandemic is affecting global health systems, endangering daily patient care. Hemato-oncological patients are particularly vulnerable to infection, requiring decisive recommendations on treatment and triage. The aim of this survey amongst experts on radiation therapy (RT) for lymphoma and leukemia is to delineate typical clinical scenarios and to provide counsel for high-quality care.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>A\u00a0multi-item questionnaire containing multiple-choice and free-text questions was developed in a\u00a0peer-reviewed process and sent to members of the radiation oncology panels of the German Hodgkin Study Group and the German Lymphoma Alliance. Answers were assessed online and analyzed centrally.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Omission of RT was only considered in a\u00a0minority of cases if alternative treatment options were available. Hypofractionated regimens and reduced dosages may be used for indolent lymphoma and fractures due to multiple myeloma. Overall, there was a\u00a0tendency to shorten RT rather than to postpone or omit it. Even in case of critical resource shortage, panelists agreed to start emergency RT for typical indications (intracranial pressure, spinal compression, superior vena cava syndrome) within 24\u202fh. Possible criteria to consider for patient triage are the availability of (systemic) options, the underlying disease dynamic, and the treatment rationale (curative\/palliative).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>RT for hemato-oncological patients receives high-priority and should be maintained even in later stages of the pandemic. Hypofractionation and shortened treatment schedules are feasible options for well-defined constellations, but have to be discussed in the clinical context.<\/jats:p>\n<\/jats:sec>","DOI":"10.1007\/s00066-020-01705-w","type":"journal-article","created":{"date-parts":[[2020,10,30]],"date-time":"2020-10-30T12:02:43Z","timestamp":1604059363000},"page":"1096-1102","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Radiation treatment of hemato-oncological patients in times of the COVID-19 pandemic"],"prefix":"10.1007","volume":"196","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2786-7013","authenticated-orcid":false,"given":"M.","family":"Oertel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Elsayad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Engenhart-Cabillic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Reinartz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Baues","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Schmidberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Vordermark","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Marnitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Lukas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Ruebe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Engert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Lenz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. T.","family":"Eich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,10,30]]},"reference":[{"key":"1705_CR1","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/S0140-6736(20)30251-8","volume":"395","author":"R Lu","year":"2020","unstructured":"Lu\u00a0R, Zhao\u00a0X, Li\u00a0J et\u00a0al (2020) Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 395:565\u2013574. https:\/\/doi.org\/10.1016\/S0140-6736(20)30251-8","journal-title":"Lancet"},{"key":"1705_CR2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.5394","author":"G Grasselli","year":"2020","unstructured":"Grasselli\u00a0G, Zangrillo\u00a0A, Zanella\u00a0A et al (2020) Baseline characteristics and outcomes of 1591 patients infected with SARS-coV\u20112 admitted to ICus of the Lombardy region, Italy. JAMA. https:\/\/doi.org\/10.1001\/jama.2020.5394","journal-title":"JAMA"},{"key":"1705_CR3","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","volume":"382","author":"W Guan","year":"2020","unstructured":"Guan\u00a0W, Ni\u00a0Z, Hu\u00a0Y et\u00a0al (2020) Clinical characteristics of Coronavirus disease 2019 in China. N\u00a0Engl J Med 382:1708\u20131720. https:\/\/doi.org\/10.1056\/NEJMoa2002032","journal-title":"N Engl J Med"},{"key":"1705_CR4","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.6775","author":"S Richardson","year":"2020","unstructured":"Richardson\u00a0S, Hirsch\u00a0JS, Narasimhan\u00a0M et al (2020) Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the new York city area. JAMA. https:\/\/doi.org\/10.1001\/jama.2020.6775","journal-title":"JAMA"},{"key":"1705_CR5","unstructured":"Johns Hopkins Univerity & Medicine Johns Hopkins Univerity&Medicine. https:\/\/coronavirus.jhu.edu\/map.html. Accessed 21 Sept 2020"},{"key":"1705_CR6","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/S1470-2045(20)30096-6","volume":"21","author":"W Liang","year":"2020","unstructured":"Liang\u00a0W, Guan\u00a0W, Chen\u00a0R et al (2020) Cancer patients in SARS-CoV\u20112 infection: a\u00a0nationwide analysis in China. Lancet Oncol 21:335\u2013337. https:\/\/doi.org\/10.1016\/S1470-2045(20)30096-6","journal-title":"Lancet Oncol"},{"key":"1705_CR7","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1001\/jama.2020.2648","volume":"323","author":"Z Wu","year":"2020","unstructured":"Wu\u00a0Z, McGoogan\u00a0JM (2020) Characteristics of and important lessons from the Coronavirus disease 2019 (COVID-19) outbreak in China: summary of a\u00a0report of 72 314 cases from the Chinese center for disease control and prevention. JAMA 323:1239. https:\/\/doi.org\/10.1001\/jama.2020.2648","journal-title":"JAMA"},{"key":"1705_CR8","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.0980","author":"J Yu","year":"2020","unstructured":"Yu\u00a0J, Ouyang\u00a0W, Chua\u00a0MLK, Xie\u00a0C (2020) SARS-coV\u20112 transmission in patients with cancer at a\u00a0tertiary care hospital in Wuhan, China. JAMA Oncol. https:\/\/doi.org\/10.1001\/jamaoncol.2020.0980","journal-title":"JAMA Oncol"},{"key":"1705_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.03.296","author":"L Zhang","year":"2020","unstructured":"Zhang\u00a0L, Zhu\u00a0F, Xie\u00a0L et al (2020) Clinical characteristics of COVID-19-infected cancer patients: a\u00a0retrospective case study in three hospitals within Wuhan, China. Ann Oncol. https:\/\/doi.org\/10.1016\/j.annonc.2020.03.296","journal-title":"Ann Oncol"},{"key":"1705_CR10","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16852","author":"JA Aries","year":"2020","unstructured":"Aries\u00a0JA, Davies\u00a0JK, Auer\u00a0RL et al (2020) Clinical Outcome of Coronavirus Disease 2019 in Haemato-oncology Patients. Br J Haematol. https:\/\/doi.org\/10.1111\/bjh.16852","journal-title":"Br J Haematol"},{"key":"1705_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-020-0931-4","author":"F Malard","year":"2020","unstructured":"Malard\u00a0F, Genthon\u00a0A, Brissot\u00a0E et al (2020) COVID-19 outcomes in patients with hematologic disease. Bone Marrow Transplant. https:\/\/doi.org\/10.1038\/s41409-020-0931-4","journal-title":"Bone Marrow Transplant"},{"key":"1705_CR12","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-0516","author":"V Mehta","year":"2020","unstructured":"Mehta\u00a0V, Goel\u00a0S, Kabarriti\u00a0R et al (2020) Case fatality rate of cancer patients with COVID-19 in a\u00a0new York hospital system. Cancer Discov. https:\/\/doi.org\/10.1158\/2159-8290.CD-20-0516","journal-title":"Cancer Discov"},{"key":"1705_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.04.006","author":"H Miyashita","year":"2020","unstructured":"Miyashita\u00a0H, Mikami\u00a0T, Chopra\u00a0N et al (2020) Do patients with cancer have a\u00a0poorer prognosis of COVID-19? An experience in new York City. Ann Oncol. https:\/\/doi.org\/10.1016\/j.annonc.2020.04.006","journal-title":"Ann Oncol"},{"key":"1705_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-020-0375-1","author":"H Nagar","year":"2020","unstructured":"Nagar\u00a0H, Formenti\u00a0SC (2020) Cancer and COVID-19\u2014potentially deleterious effects of delaying radiotherapy. Nat Rev Clin Oncol. https:\/\/doi.org\/10.1038\/s41571-020-0375-1","journal-title":"Nat Rev Clin Oncol"},{"key":"1705_CR15","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020006028","author":"J Yahalom","year":"2020","unstructured":"Yahalom\u00a0J, Dabaja\u00a0BS, Ricardi\u00a0U et al (2020) ILROG emergency guidelines for radiation therapy of hematological malignancies during the COVID-19 pandemic. Blood. https:\/\/doi.org\/10.1182\/blood.2020006028","journal-title":"Blood"},{"key":"1705_CR16","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s13014-020-01527-1","volume":"15","author":"SE Combs","year":"2020","unstructured":"Combs\u00a0SE, Belka\u00a0C, Niyazi\u00a0M et al (2020) First statement on preparation for the COVID-19 pandemic in large German Speaking University-based radiation oncology departments. Radiat Oncol 15:74. https:\/\/doi.org\/10.1186\/s13014-020-01527-1","journal-title":"Radiat Oncol"},{"key":"1705_CR17","unstructured":"Deutsche Gesellschaft f\u00fcr Radioonkologie (DEGRO) Hypofraktionierte Bestrahlungs-Regimes als Alternative zu konventioneller Bestrahlung in Zeiten reduzierter Strahlentherapie-Kapazit\u00e4ten https:\/\/www.degro.org\/wp-content\/uploads\/2020\/03\/Hypofraktionierte-Bestrahlungsregimes.pdf. Accessed: 05 July 2020"},{"key":"1705_CR18","unstructured":"Deutsche Gesellschaft f\u00fcr Radioonkologie (DEGRO) ARO, Berufsverband Deutscher Strahlentherapeuten Stellungnahme der ARO, DEGRO und des Berufsverbandes zur Strahlentherapie w\u00e4hrend der COVID-19 Pandemie https:\/\/www.degro.org\/wp-content\/uploads\/2020\/03\/Corona.pdf. Accessed: 05.July 2020"},{"key":"1705_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2020.04.001","author":"M Guckenberger","year":"2020","unstructured":"Guckenberger\u00a0M, Belka\u00a0C, Bezjak\u00a0A et al (2020) Practice recommendations for lung cancer radiotherapy during the COVID-19 pandemic: An ESTRO-ASTRO consensus statement. Radiother Oncol. https:\/\/doi.org\/10.1016\/j.radonc.2020.04.001","journal-title":"Radiother Oncol"},{"key":"1705_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2020.04.016","author":"DJ Thomson","year":"2020","unstructured":"Thomson\u00a0DJ, Palma\u00a0D, Guckenberger\u00a0M et al (2020) Practice recommendations for risk-adapted head and neck cancer radiotherapy during the COVID-19 pandemic: an ASTRO-ESTRO consensus statement. Int J Radiat Oncol Biol Phys. https:\/\/doi.org\/10.1016\/j.ijrobp.2020.04.016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1705_CR21","unstructured":"German society of radiation oncology (DEGRO) (2020) 2. Stellungnahme der ARO, DEGRO und des Berufsverbandes zur Strahlentherapie w\u00e4hrend der COVID-19 Pandemie https:\/\/www.degro.org\/wp-content\/uploads\/2020\/03\/Corona.pdf. Accessed: 05 July 2020"},{"key":"1705_CR22","unstructured":"Robert-Koch-Institut (2020) Informationen und Hilfestellungen f\u00fcr Personen mit einem h\u00f6heren Risiko f\u00fcr einen schweren COVID-19-Krankheitsverlauf. https:\/\/www.rki.de\/DE\/Content\/InfAZ\/N\/Neuartiges_Coronavirus\/Risikogruppen.html?nn=13490888. Accessed 16 May 2020"},{"key":"1705_CR23","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1093\/jnci\/djs629","volume":"105","author":"SC Formenti","year":"2013","unstructured":"Formenti\u00a0SC, Demaria\u00a0S (2013) Combining radiotherapy and cancer immunotherapy: a paradigm shift. JNCI J Natl Cancer Inst 105:256\u2013265. https:\/\/doi.org\/10.1093\/jnci\/djs629","journal-title":"JNCI J Natl Cancer Inst"},{"key":"1705_CR24","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s00066-018-1287-1","volume":"194","author":"M R\u00fcckert","year":"2018","unstructured":"R\u00fcckert\u00a0M, Deloch\u00a0L, Fietkau\u00a0R et al (2018) Immune modulatory effects of radiotherapy as basis for well-reasoned radioimmunotherapies. Strahlenther Onkol 194:509\u2013519. https:\/\/doi.org\/10.1007\/s00066-018-1287-1","journal-title":"Strahlenther Onkol"},{"key":"1705_CR25","doi-asserted-by":"publisher","DOI":"10.3332\/ecancer.2020.1023","author":"B Russell","year":"2020","unstructured":"Russell\u00a0B, Moss\u00a0C, Rigg\u00a0A, Van Hemelrijck\u00a0M (2020) COVID-19 and treatment with NSAIDs and corticosteroids: should we be limiting their use in the clinical setting? Ecancermedicalscience. https:\/\/doi.org\/10.3332\/ecancer.2020.1023","journal-title":"Ecancermedicalscience"},{"key":"1705_CR26","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1148\/rg.244035160","volume":"24","author":"YW Choi","year":"2004","unstructured":"Choi\u00a0YW, Munden\u00a0RF, Erasmus\u00a0JJ et\u00a0al (2004) Effects of radiation therapy on the lung: radiologic appearances and differential diagnosis. Radiographics 24:985\u2013997. https:\/\/doi.org\/10.1148\/rg.244035160 (discussion 998)","journal-title":"Radiographics"},{"key":"1705_CR27","unstructured":"Deutsche R\u00f6ntgengesellschaft (2020) COVID-19 \u2013 Information der AG Thoraxdiagnostik der Deutschen R\u00f6ntgengesellschaft. https:\/\/www.drg.de\/de-DE\/5995\/covid-19\/. Accessed 16 May 2020"},{"issue":"17","key":"1705_CR28","first-page":"A-872\/B-732","volume":"117","author":"V Zylka-Menhorn","year":"2020","unstructured":"Zylka-Menhorn\u00a0V (2020) Radiologie und COVID-19: Ein Lungen-CT nicht ohne rechtfertigende Indikation. Dtsch Arztebl 117(17):A-872\/B-732","journal-title":"Dtsch Arztebl"},{"key":"1705_CR29","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1016\/j.ijrobp.2005.10.018","volume":"64","author":"D Rades","year":"2006","unstructured":"Rades\u00a0D, Hoskin\u00a0PJ, Stalpers\u00a0LJA et al (2006) Short-course radiotherapy is not optimal for spinal cord compression due to myeloma. Int J Radiat Oncol Biol Phys 64:1452\u20131457. https:\/\/doi.org\/10.1016\/j.ijrobp.2005.10.018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1705_CR30","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s13014-019-1265-5","volume":"14","author":"M Oertel","year":"2019","unstructured":"Oertel\u00a0M, Elsayad\u00a0K, Kroeger\u00a0KJ et\u00a0al (2019) Impact of radiation dose on local control and survival in extramedullary head and neck plasmacytoma. Radiat Oncol 14:63. https:\/\/doi.org\/10.1186\/s13014-019-1265-5","journal-title":"Radiat Oncol"},{"key":"1705_CR31","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/S0360-3016(02)02780-3","volume":"53","author":"P Strojan","year":"2002","unstructured":"Strojan\u00a0P, \u0160oba\u00a0E, Lamovec\u00a0J, Munda\u00a0A (2002) Extramedullary plasmacytoma: clinical and histopathologic study. Int J Radiat Oncol 53:692\u2013701. https:\/\/doi.org\/10.1016\/S0360-3016(02)02780-3","journal-title":"Int J Radiat Oncol"},{"key":"1705_CR32","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1016\/j.ijrobp.2018.05.009","volume":"101","author":"RW Tsang","year":"2018","unstructured":"Tsang\u00a0RW, Campbell\u00a0BA, Goda\u00a0JS et\u00a0al (2018) Radiation therapy for solitary plasmacytoma and multiple myeloma: guidelines from the international lymphoma radiation oncology group. Int J Radiat Oncol Biol Phys 101:794\u2013808. https:\/\/doi.org\/10.1016\/j.ijrobp.2018.05.009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1705_CR33","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.1200\/JCO.19.00964","volume":"37","author":"M Fuchs","year":"2019","unstructured":"Fuchs\u00a0M, Goergen\u00a0H, Kobe\u00a0C et al (2019) Positron emission tomography-guided treatment in early-stage favorable hodgkin lymphoma: final results of the international, randomized phase III HD16 trial by the German Hodgkin study group. J\u00a0Clin Oncol 37:2835\u20132845. https:\/\/doi.org\/10.1200\/JCO.19.00964","journal-title":"J Clin Oncol"},{"key":"1705_CR34","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1056\/NEJMoa1408648","volume":"372","author":"J Radford","year":"2015","unstructured":"Radford\u00a0J, Illidge\u00a0T, Counsell\u00a0N et al (2015) Results of a\u00a0trial of PET-directed therapy for early-stage Hodgkin\u2019s lymphoma. N\u00a0Engl J Med 372:1598\u20131607. https:\/\/doi.org\/10.1056\/NEJMoa1408648","journal-title":"N Engl J Med"},{"key":"1705_CR35","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1200\/JCO.2013.51.9298","volume":"32","author":"JMM Raemaekers","year":"2014","unstructured":"Raemaekers\u00a0JMM, Andr\u00e9\u00a0MPE, Federico\u00a0M et al (2014) Omitting radiotherapy in early positron emission tomography-negative stage I\/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC\/LYSA\/FIL H10 trial. J\u00a0Clin Oncol 32:1188\u20131194. https:\/\/doi.org\/10.1200\/JCO.2013.51.9298","journal-title":"J Clin Oncol"},{"key":"1705_CR36","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/S1470-2045(14)70036-1","volume":"15","author":"PJ Hoskin","year":"2014","unstructured":"Hoskin\u00a0PJ, Kirkwood\u00a0AA, Popova\u00a0B et al (2014) 4\u202fGy versus 24\u202fGy radiotherapy for patients with indolent lymphoma (FORT): a\u00a0randomised phase 3 non-inferiority trial. Lancet Oncol 15:457\u2013463. https:\/\/doi.org\/10.1016\/S1470-2045(14)70036-1","journal-title":"Lancet Oncol"},{"key":"1705_CR37","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.radonc.2011.05.013","volume":"100","author":"L Lowry","year":"2011","unstructured":"Lowry\u00a0L, Smith\u00a0P, Qian\u00a0W et al (2011) Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a\u00a0randomised phase III trial. Radiother Oncol 100:86\u201392. https:\/\/doi.org\/10.1016\/j.radonc.2011.05.013","journal-title":"Radiother. Oncol."},{"key":"1705_CR38","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1159\/000475634","volume":"40","author":"K Elsayad","year":"2017","unstructured":"Elsayad\u00a0K, Susek\u00a0KH, Eich\u00a0HT (2017) Total skin electron beam therapy as part of multimodal treatment strategies for primary cutaneous T\u2011cell lymphoma. Oncol Res Treat 40:244\u2013252. https:\/\/doi.org\/10.1159\/000475634","journal-title":"Oncol Res Treat"},{"key":"1705_CR39","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1007\/s00066-018-1277-3","volume":"194","author":"L K\u00f6nig","year":"2018","unstructured":"K\u00f6nig\u00a0L, H\u00f6rner-Rieber\u00a0J, Bernhardt\u00a0D et al (2018) Response rates and recurrence patterns after low-dose radiotherapy with 4\u202fGy in patients with low-grade lymphomas. Strahlenther Onkol 194:454\u2013461. https:\/\/doi.org\/10.1007\/s00066-018-1277-3","journal-title":"Strahlenther Onkol"},{"key":"1705_CR40","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1007\/s00066-016-0962-3","volume":"192","author":"L K\u00f6nig","year":"2016","unstructured":"K\u00f6nig\u00a0L, Stade\u00a0R, Rieber\u00a0J et\u00a0al (2016) Radiotherapy of indolent orbital lymphomas: two radiation concepts. Strahlenther Onkol 192:414\u2013421. https:\/\/doi.org\/10.1007\/s00066-016-0962-3","journal-title":"Strahlenther Onkol"},{"key":"1705_CR41","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1007\/s00066-019-01541-7","volume":"196","author":"M Oertel","year":"2020","unstructured":"Oertel\u00a0M, Elsayad\u00a0K, Weishaupt\u00a0C et al (2020) De-escalated radiotherapy for indolent primary cutaneous B\u2011cell lymphoma. Strahlenther Onkol 196:126\u2013131. https:\/\/doi.org\/10.1007\/s00066-019-01541-7","journal-title":"Strahlenther Onkol"},{"key":"1705_CR42","volume-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","author":"World Health Organization","year":"2017","unstructured":"World Health Organization (2017) WHO classification of tumours of haematopoietic and lymphoid tissues, 4th\u00a0edn. International Agency for Research on Cancer, Lyon","edition":"4"},{"key":"1705_CR43","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.ijrobp.2018.04.071","volume":"101","author":"JYC Wong","year":"2018","unstructured":"Wong\u00a0JYC, Filippi\u00a0AR, Dabaja\u00a0BS et\u00a0al (2018) Total body irradiation: guidelines from the international Lymphoma radiation oncology group (ILROG). Int J Radiat Oncol Biol Phys 101:521\u2013529. https:\/\/doi.org\/10.1016\/j.ijrobp.2018.04.071","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1705_CR44","unstructured":"Deutscher Ethikrat (2020) Solidarity and responsibility during the Coronavirus crisis\u2014ad hoc recommendation. https:\/\/www.ethikrat.org\/publikationen\/publikationsdetail\/?tx_wwt3shop_detail%5Bproduct%5D=135&tx_wwt3shop_detail%5Baction%5D=index&tx_wwt3shop_detail%5Bcontroller%5D=Products&cHash=a37377aedcc6b8b131fce9a9146f9095. Accessed 16 May 2020"}],"container-title":["Strahlentherapie und Onkologie"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-020-01705-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00066-020-01705-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-020-01705-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,24]],"date-time":"2020-11-24T13:18:36Z","timestamp":1606223916000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00066-020-01705-w"}},"subtitle":["Expert recommendations from the radiation oncology panels of the German Hodgkin Study Group and the German Lymphoma Alliance"],"short-title":[],"issued":{"date-parts":[[2020,10,30]]},"references-count":44,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1705"],"URL":"https:\/\/doi.org\/10.1007\/s00066-020-01705-w","relation":{},"ISSN":["0179-7158","1439-099X"],"issn-type":[{"value":"0179-7158","type":"print"},{"value":"1439-099X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,30]]},"assertion":[{"value":"2 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.\u00a0Oertel, K.\u00a0Elsayad, R.\u00a0Engenhart-Cabillic, G.\u00a0Reinartz, C.\u00a0Baues, H.\u00a0Schmidberger, D.\u00a0Vordermark, S.\u00a0Marnitz, P.\u00a0Lukas, C.\u00a0Ruebe, A.\u00a0Engert, G.\u00a0Lenz, and H.T.\u00a0Eich declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}